VEGFA and hypoparathyroidism-retardation-dysmorphism syndrome: It was also reported that inhibition of the vascular endothelial growth factor (VEGF) causes a certain level of HRD that could be further exploited by PARPi, but results from the Phase III PAOLA-1 trial showed the benefit of the combination of olaparib and the VEGF inhibitor bevacizumab only in the HRD population [15].